Dr. Ripen Misri is a post-doctoral researcher at the BC Cancer Research Centre. Dr. Misri obtained his PhD in pharmaceutical sciences from the University of British Columbia. His research interests are in using nanoparticle drug delivery approaches for improving treatment of cancers.
A major challenge in cancer therapy is to deliver efficacious doses of drug to diseased tissue with minimal toxicity to normal tissues. Dr. Misri’s post-doctoral research focuses on using rationally designed polymeric nanoparticles for tumour-specific targeting and controlled delivery of chemotherapeutic drugs; with the purpose of increasing their efficacy and reducing toxicity.
Misri R, Saatchi K, Häfeli UO. Nanoprobes for hybrid SPECT/MR molecular imaging. Nanomedicine (Lond). 2012 May;7(5):719-33. doi: 10.2217/nnm.12.32. (PubMed abstract)
Misri R, Meier D, Yung AC, Kozlowski P, Häfeli UO. Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe. Nanomedicine. 2012 Aug;8(6):1007-16. doi: 10.1016/j.nano.2011.10.013. Epub 2011 Nov 16. (PubMed abstract)
Misri R, Saatchi K, Ng SS, Kumar U, Häfeli UO. Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nucl Med Biol. 2011 Aug;38(6):885-96. doi: 10.1016/j.nucmedbio.2011.02.013. Epub 2011 Apr 21. (PubMed abstract)
Misri R, Saatchi K, Häfeli UO. Radiolabeling of fab and f(ab’)2 antibody fragments with 99mTc(I) tricarbonyl core using a new bifunctional tridentate ligand. Nucl Med Commun. 2011 Apr;32(4):324-9. doi: 10.1097/MNM.0b013e328343dee5. (PubMed abstract)
Häfeli UO, Saatchi K, Elischer P, Misri R, Bokharaei M, Labiris NR, Stoeber B. Lung perfusion imaging with monosized biodegradable microspheres. Biomacromolecules. 2010 Mar 8;11(3):561-7. doi: 10.1021/bm9010722. (PubMed abstract)